IONS Overview

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is92.67 USD with a low forecast of 65.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ionis Pharmaceuticals Inc revenue for the last quarter amounts to 203.33M USD, decreased -10.26

Ionis Pharmaceuticals Inc. EPS for the last quarter amounts to -1.41 USD, increased 113.64

Ionis Pharmaceuticals Inc (IONS) has 1402 emplpoyees as of April 20 2026.

Today IONS has the market capitalization of 12.51B USD.